Clinical Study | Office of Clinical Research

Primary Biliary Cholangitis (Pbc) Clinical Trial

Posted Date: Oct 7, 2021

Investigator: Kenneth Sherman
Specialties: Gastroenterology, Liver Disease
Type of Study: Drug

TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness

Criteria:

Eligible Patients Must Have A Diagnosis Of Pbc.

Keywords:

Pbc, Cirrhosis, Fibrosis

For More Information:

Liz Stambrook
513-584-2363
stambre@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List